Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma

Multiple myeloma (MM) is a malignant plasma cell disorder characterized by abnormal proliferation of bone marrow plasma cells accompanied by excessive production of monoclonal immunoglobulin or light chains (M-protein). It is frequently associated with multiple osteolytic lesions, hypercalcemia, anemia, and renal impairment. The disease has an incidence rate of 2-3 per 100,000, with a male-to-female ratio of 1.6:1, predominantly affecting individuals over 40 years of age.

Traditional treatments for MM include chemotherapy regimens such as MP (melphalan + prednisone), VAD (vincristine + doxorubicin + dexamethasone), and CTD (cyclophosphamide + thalidomide + dexamethasone), as well as radiotherapy and autologous hematopoietic stem cell transplantation (ASCT). However, these approaches are limited by low induction remission rates and short long-term survival.

In recent years, the introduction of novel agents such as proteasome inhibitors (e.g., bortezomib) and immunomodulatory agents (e.g., lenalidomide) has significantly improved remission rates and reduced chemotherapy-related toxicity, extending the median survival of MM patients from 2-3 years to over 5 years. For transplant-eligible patients, intensive induction therapy followed by ASCT remains the current first-line treatment strategy. For relapsed/refractory MM, next-generation oral proteasome inhibitors (e.g., ixazomib), monoclonal antibodies (e.g., daratumumab), and targeted cellular immunotherapies have demonstrated promising efficacy.

Nevertheless, MM remains incurable, and with each relapse, the likelihood of acquiring high-risk cytogenetic abnormalities increases, leading to escalating treatment resistance. Consequently, subsequent relapses are associated with shorter progression-free survival and post-relapse survival durations. Therefore, there is an urgent need to explore more effective therapeutic strategies to improve outcomes and prolong survival in MM patients with high-risk features or suboptimal depth of response.

The treatment of multiple myeloma (MM) with transplantation has evolved through several stages, including autologous stem cell transplantation (auto-HSCT), allogeneic hematopoietic stem cell transplantation (allo-HSCT), and sequential auto-HSCT followed by allo-HSCT. However, due to factors such as the advanced median age at diagnosis of MM patients, allo-HSCT has not become the first-line treatment for most newly diagnosed MM patients.

The sequential approach-first performing auto-HSCT to reduce tumor burden, followed by reduced-intensity allo-HSCT-has shown conflicting clinical efficacy reports, limiting its widespread adoption. Consequently, auto-HSCT remains the primary treatment modality for transplant-eligible MM patients.

Since its introduction in the early 1980s, auto-HSCT has significantly prolonged overall survival (OS) in MM patients and has been regarded as the preferred treatment for newly diagnosed MM patients aged ≤65 years. However, with the emergence of novel drugs (e.g., proteasome inhibitors, immunomodulators, CD38 monoclonal antibodies), the complete response (CR) rate after 4-6 cycles of induction therapy has reached 20%-40%, raising questions about the necessity of auto-HSCT.

Prospective clinical trials comparing auto-HSCT combined with novel agents versus continuous novel drug therapy have demonstrated that auto-HSCT provides greater progression-free survival (PFS)benefits, reaffirming its critical role in newly diagnosed MM. Even with monoclonal antibody-based induction regimens, auto-HSCT remains a cornerstone of treatment for eligible patients.

In summary, despite advancements in pharmacotherapy, auto-HSCT continues to play an indispensable role in achieving deeper remission and prolonging survival** for transplant-eligible MM patients